Type II diabetes drugs including Invokana, Jardiance, Farxiga, and Invokamet are linked to serious injuries including Diabetic Ketoacidosis, Kindey Failure, Bladder Cancer and others. Lawsuits are moving forward quickly with expiration dates approaching.
See if you qualify for Invokana or Other Type II Diabetes Drug litigation and the right to potentially significant financial recovery.
The Invokana Instant Case Evaluator provides lawsuit qualification information and details regarding your situation.
On May 15, 2015 FDA issued a safety warning that the type-2 diabetes mellitus (DM) drugs canagliflozin (Invokana, Johnson & Johnson), dapagliflozin (Farxiga, AstraZeneca plc) and empagliflozin (Jardiance, Boehringer Ingelheim GmbH and Eli Lilly & Company) belonging to SGLT-2 class inhibitors may cause diabetic ketoacidosis, a serious condition that makes blood acidic due to the presence of ketones.
SGLT-2 inhibitors (including Invokana, Farxiga and Jardiance) are a class of FDA approved drugs prescribed for type-2 diabetes patients in conjunction with diet and exercise to lower blood glucose levels. These drugs block glucose reabsorption from the kidney, thus increasing urinary glucose excretion and reducing blood glucose levels.
Diabetic Ketoacidosis is an acute metabolic complication of diabetes, also referred to as diabetic ketoacidosis (DKA). DKA occurs when insulin levels are inadequate to meet the body’s basic metabolic requirements. Insulin deficiency leads to formation of free fatty acids due to breakdown of triglycerides and amino acids, which get converted to highly acidic ketone bodies, leading to acidosis. Symptoms include nausea, vomiting, and abdominal pain that can progress to kidney failure, cerebral edema, coma, and death.
According to the FDA safety alert, patients should stop taking their SGLT2 inhibitor and seek medical attention immediately if they have any symptoms of ketoacidosis, a serious condition in which the body produces high levels of blood acids called ketones.
Did you use one of these medications?
Did you then develop any of these complications?
Other Kidney Problems
If you answered yes to these two questions you should look into your legal rights. Fill out our Secure Invokana Instant Case Evaluation if you believe you may need to protect your legal rights.
Instant, Secure, No cost/No obligation Analysis of Your Invokana Lawsuit
Thank you for using the Instant Case Evaluator sponsored by TruLaw LLC.
By utilizing the Instant Case Evaluator, or the links accessible through this site, you expressly agree to be bound by this agreement. The information and the resources contained on and accessible through this site are made available by TruLaw LLC and are subject to your agreement to their terms and conditions.
No attorney/client relationship is established with use of the Instant Case Evaluator, our website, our 24/7 chat service or through submitting information via email, posting on our social media sites or calling our offices.
TruLaw utilizes a number of tools to provide potential clients with instant feedback including chat services and instant case analysis. Please understand that contacting TruLaw through any one of these vehicles or via phone or email does not create an attorney/client relationship and an attorney-client privilege does not exist. Attorney-client privilege is an important legal concept that protects certain communications between a client and his/her attorney. None of the information submitted through this website, online chats, emails or phone calls is protected until we have a contract that establishes an attorney-client relationship. Our lawyers must make a case-by-case assessment of any claims and results may vary depending on the facts concerning any case. We reserve the right to decline any representation.
We do not collect personal identifying information from users of this site unless provided by the visitor. Information you provide will only be used to respond to inquiries or future emails/mailings. TruLaw LLC will not sell or give your information to third parties; we will use this only for TruLaw marketing purposes and our affiliated companies. You are always welcome to request to have your information removed from future emails/mailings. Please understand that personal information submitted to our website via email, live chat, submission through a survey or instant case evaluator, responding to a blog or social media post is not 100 percent secure and you should take this into account when submitting personal or confidential data about yourself.
Links from this web site do not imply or state a relationship or endorsement between the linked site and TruLaw LLC. TruLaw LLC is not responsible for the content of any other site.
TruLaw attempts to keep all information up to date and accurate but we provide no warranties as to the accuracy or reliability of the information provided on our website, on our blog or on the social media pages/accounts that we sponsor. In addition, TruLaw makes no warranties about the accuracy or reliability about the links or information provided on our site by other parties.
This website is maintained by TruLaw, LLC. Jessica Paluch Hoerman is the responsible attorney for this website. Jessica can be reached at Jess@TruLaw.com or at the address, phone number and email provided on this website.
Mar 29, 2013
May 01, 2014
FDA Warns of Acute Kidney Injury and Impairment in Renal Function
The FDA identified 19 cases of life-threatening blood infections (urosepsis) and kidney infections (pyelonephritis) that started as urinary tract infections with the SGLT2 inhibitors reported to FAERS from March 2013 through October 2014. All 19 patients identified were hospitalized, and a few required admission to an intensive care unit or dialysis in order to treat kidney failure.
According to an FDA review of the FDA Adverse Event Reporting System (FAERS) database from March 2013 to May 2015, 73 cases of ketoacidosis in patients with type 1 or type 2 diabetes treated with SGLT2 inhibitors.
In February 2016, the European Medicines Agency (EMA) confirmed recommendations to minimize the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors including Invokana, Farxiga and Jardiance. According to the EMA notice, patients taking these medicines need to be aware of the symptoms of diabetic ketoacidosis (DKA)
According to Advera Health’s RX Signal, the number of individuals experiencing diabetic ketoacidosis noted by the FDA is understated. According to Advera health, there were 71 cases of DKA from Invokana use and 28 cases of DKA with Farxiga use. These reported numbers are likely to increase as more individuals become aware of the link between SLGT-2 inhibitors and ketoacidosis.